HighTower Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-100
Closed -$299 3834
2025
Q3
$299 Hold
100
﹤0.01% 3784
2025
Q2
$4.67K Sell
100
-800
-89% -$622K ﹤0.01% 3684
2025
Q1
$27.6K Buy
+900
New +$749K ﹤0.01% 3500
2024
Q3
Sell
-700
Closed -$13.7K 3869
2024
Q2
$13.7K Buy
700
+400
+133% +$320K ﹤0.01% 3424
2024
Q1
$4.54K Sell
300
-500
-63% -$356K ﹤0.01% 3448
2023
Q4
$13.2K Buy
800
+746
+1,381% +$435K ﹤0.01% 3423
2023
Q3
$13.3K Buy
54
+49
+980% +$25.2K ﹤0.01% 3364
2023
Q2
$22.9K Sell
5
-195
-98% -$81.8K ﹤0.01% 3245
2023
Q1
$510 Buy
+200
New +$67.5K ﹤0.01% 3324
2022
Q1
Sell
-1
Closed -$15K 3557
2021
Q4
$15K Buy
+1
New +$254 ﹤0.01% 3135

Other funds holding LLY

HighTower Advisors's LLY Position: Q2 2026 in Review

HighTower Advisors reduced its Eli Lilly (LLY) stake by 0.96% in Q2 2026, selling an estimated $4.33M and leaving 436,561 shares worth $524M. The position accounts for 0.5% of the portfolio, ranked #30.

HighTower Advisors first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. The position peaked at $524M in Q4 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • HighTower Advisors held 436,561 shares of Eli Lilly worth $524M as of Q2 2026.
  • HighTower Advisors sold 4,236 Eli Lilly shares in Q2 2026, an estimated $4.33M.
  • Eli Lilly made up 0.5% of HighTower Advisors's portfolio in Q2 2026, its #30 holding.
  • HighTower Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • HighTower Advisors's Eli Lilly position peaked at $524M in Q4 2025.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.